Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Office of Research & Development

print icon sign up for VA Research updates

Funded Project Details - FY2021




Project Number:

I01BX004497-01A2
Title: CCN5 Therapy for Triple Negative Breast Cancer
Principal Investigator:

Sushanta K. Banerjee

Location: Kansas City, MO
Congressional District Code: 5
Research Service: Biomedical Laboratory R&D
Project Period: October 2019 - September 2023
FY 2021 Funding Amount: $329,302
Total Award Amount
(all years):
$1,540,986
Abstract: View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER


Excerpt:

Current therapies for breast cancer (BC) are firmly believed to improve patient survival efficiently. However, one-third of aggressive triple-negative breast cancer (TNBC) patients may relapse more frequently compared to hormone receptor-positive subtypes, and patients may eventually develop the distant metastatic disease and drug resistance. There are no targeted therapies currently available for invasive and metastatic diseases, indicating a dire need for improved therapy. We revealed that CCN...



Questions about the R&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.